Engel Law PLLC is investigating whether fair value to BELLUS shareholders will result from the proposed acquisition of BELLUS Health Inc. (NASDAQ: BLU) by GSK plc for $14.75 in cash for each BELLUS share.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.